This stock is a great choice for cautious and aggressive investors.

Get the live share price of Moderna Inc (MRNA), including intraday charts, historical performance, key financials, and market ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

Moderna earns the No. 356 rank among its peers in the Medical-Biomed/Biotech industry group. Exact Sciences EXAS, Genmab ADR GMAB and Krystal Biotech KRYS are among the top 5 highly rated stocks ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the afternoon session after the broader biotech sector experienced a strong rebound, lifting shares of companies within the industry.

Since that moment, Moderna has taken steps to pave the path to long-term growth -- from cutting costs to focusing on its vast pipeline. Considering the full picture, now, with the stock down 80% over ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower on Friday afternoon, giving back a portion of the gains seen on Thursday. Here’s what investors need to know. What To Know: The stock spiked on ...

Moderna (MRNA) closed the most recent trading day at $32.29, moving -7.48% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.46%. Elsewhere, the Dow ...

In the latest trading session, Moderna (MRNA) closed at $30.41, marking a -2.38% move from the previous day. This move lagged ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.0 to $39.0 for Moderna over the last 3 months.

Moderna, Inc. has rallied ~23%, but rated a Sell due to deteriorating fundamentals. Learn more about MRNA stock here.

Moderna MRNA is set to report third-quarter 2025 earnings on Nov. 6, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $860 million and a loss of $2.15 per ...